TapewireFind a company

person · Reporting owner

Malenka Robert C.

Disclosed activity across 1 company

Tapewire entity
52093
SEC CIK
0002021198

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
MapLight Therapeutics, Inc.MPLT · Entity 5316DirectorApril 15, 2026April 17, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

MapLight Therapeutics, Inc.

Report date April 15, 2026 · Filed April 17, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Voting Common StockSEC Table I · non-derivativeDirect316,466 Reported balance After 2026-04-15 transaction · row 1
1 source row

Row 1 · 2026-04-15 · Sale · Disposed 8,593 · Balance 316,466

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Voting Common StockSEC Table I · non-derivativeIndirectSee footnote31,672 Reported balance Holding disclosure · report date 2026-04-15 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 31,672

F3: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

F2: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
April 15, 2026 Filed Apr 17, 2026 20:05 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 8,593 $26.90 $231,151.70
Disclosure

SEC source: 0002021198-26-000013 · form4-04172026_040402.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 316,466

F1 · kind: This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $26.35 to $27.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 24, 2026 Filed Feb 24, 2026 23:57 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 736 $18.15 $13,358.40
Disclosure

SEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 4

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,059

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $18.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 23, 2026 Filed Feb 24, 2026 23:57 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 476 $19.06 $9,072.56
Disclosure

SEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 3

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 325,795

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.00 to $19.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 23, 2026 Filed Feb 24, 2026 23:57 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 10,788 $18.39 $198,391.32
Disclosure

SEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 2

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 326,271

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 20, 2026 Filed Feb 24, 2026 23:57 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 2,195 $18.03 $39,575.85
Disclosure

SEC source: 0002021198-26-000011 · form4-02242026_110209.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 337,059

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 13, 2026 Filed Feb 19, 2026 00:33 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 12,116 $18.21 $220,632.36
Disclosure

SEC source: 0002021198-26-000009 · form4-02192026_120233.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 339,254

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 11, 2026 Filed Feb 12, 2026 22:45 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 241 $18.00 $4,338.00
Disclosure

SEC source: 0002021198-26-000007 · form4-02122026_050201.xml · nonDerivative · entry 2

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,370

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

Read SEC document
February 10, 2026 Filed Feb 12, 2026 22:45 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 6,622 $18.12 $119,990.64
Disclosure

SEC source: 0002021198-26-000007 · form4-02122026_050201.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 351,611

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
February 03, 2026 Filed Feb 5, 2026 02:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 1 $18.00 $18.00
Disclosure

SEC source: 0002021198-26-000005 · form4-02052026_020204.xml · nonDerivative · entry 2

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,233

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

Read SEC document
February 02, 2026 Filed Feb 5, 2026 02:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 7,039 $18.02 $126,842.78
Disclosure

SEC source: 0002021198-26-000005 · form4-02052026_020204.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 358,234

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 30, 2026 Filed Jan 31, 2026 01:50 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 6,612 $18.11 $119,743.32
Disclosure

SEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 4

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 365,273

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F5 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.00 to $18.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 29, 2026 Filed Jan 31, 2026 01:50 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 21,262 $18.55 $394,410.10
Disclosure

SEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 3

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 371,885

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F4 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.13 to $19.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 01:50 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 664 $19.05 $12,649.20
Disclosure

SEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 2

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,147

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F3 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $19.02 to $19.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
January 28, 2026 Filed Jan 31, 2026 01:50 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 SaleVoting Common Stock 5,860 $18.61 $109,054.60
Disclosure

SEC source: 0002021198-26-000003 · form4-01312026_010139.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 393,811

F1 · shares: Represents sales of shares of common stock by the Reporting Person to cover tax obligations in connection with the settlement of restricted stock unit awards. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. The securities of the Issuer retained by the Reporting Person remain subject to the terms a lock-up agreement entered into with the underwriters for the Issuer's initial public offering, pursuant to which the Reporting Person agreed, subject to certain exceptions, not to directly or indirectly sell or otherwise transfer securities of the Issuer for a period of 180 days following the date of the final prospectus relating to the initial public offering, which was October 26, 2025.

F2 · price: The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $18.01 to $19.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Read SEC document
October 28, 2025 Filed Oct 28, 2025 20:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 ConversionSeries C Preferred Stock · Derivative 65,477 $0.00 $0.00
Disclosure

SEC source: 0002021198-25-000006 · form4-10282025_041005.xml · derivative · entry 4

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Voting Common Stock · 3,895 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4 · ownership.nature: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

Read SEC document
October 28, 2025 Filed Oct 28, 2025 20:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 ConversionVoting Common Stock 3,895 Not disclosed Not disclosed
Disclosure

SEC source: 0002021198-25-000006 · form4-10282025_041005.xml · nonDerivative · entry 2

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 31,672

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series C Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-16.8 basis, and had no expiration date.

F4 · ownership.nature: The shares are held by the Robert C. Malenka Living Trust U/A DTD 08/21/2012, of which the Reporting Person is the sole trustee and has voting and dispositive power.

Read SEC document
October 27, 2025 Filed Oct 28, 2025 20:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 GrantEmployee Stock Option (right to buy) · Derivative 139,610 $0.00 Strike: $17.00 $0.00
Disclosure

SEC source: 0002021198-25-000006 · form4-10282025_041005.xml · derivative · entry 3

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 139,610

Underlying: Voting Common Stock · 139,610 shares

Expires 2035-10-26

F5 · derivative.exercise_date: 1/4th of the total shares underlying the option shall vest on October 1, 2026, and 1/48th of the total shares shall vest each month thereafter on the same day of the month, subject to the Reporting Person's continued service through each vesting date.

Read SEC document
October 27, 2025 Filed Oct 28, 2025 20:15 UTC MapLight Therapeutics, Inc. MPLT · Entity 5316 GrantVoting Common Stock 34,390 $0.00 $0.00
Disclosure

SEC source: 0002021198-25-000006 · form4-10282025_041005.xml · nonDerivative · entry 1

Malenka Robert C. · CIK 0002021198 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 399,671

F1 · shares: Represents a restricted stock unit ("RSU") award. 25% of the RSUs shall vest on October 1, 2026, and 1/16th of the RSUs shall vest on each subsequent January 1, April 1, July 1 and October 1 thereafter, subject to the Reporting Person's continued service through each vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.